Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Ferozsons Laboratories Ltd..
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Dr. Tariq Ashraf, Ferozsons Laboratories Ltd. Identifier:
First received: July 18, 2011
Last updated: December 7, 2011
Last verified: December 2011
This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.

Condition Intervention Phase
Chronic Stable Angina
Drug: Nicorandil
Drug: Atenolol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina.

Resource links provided by NLM:

Further study details as provided by Ferozsons Laboratories Ltd.:

Primary Outcome Measures:
  • SPECT Tc99m- Tetrofosmin (MYOVIEW) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

    Changes in perfusion will be evaluated in each arm at week 4 and comparison between the two study arms will be made to document the anti ischemic effects of nicorandilusing Ex- SPECT MPI.

    • Improvement in SDS after 4 weeks of treatment (Summed Stress Score SSS, Summed Rest Score SRS, Summed Difference Score SDS)
    • Difference in number of reversible, partially reversible defects.
    • Improvement in the extent and severity of ischemic lesions.

Secondary Outcome Measures:
  • Exercise ECG Testing - Bruce protocol [ Time Frame: 4weeks ] [ Designated as safety issue: No ]

    Secondary outcome measures of the study are the difference of the following endpoints from the baseline and comparison between control and study arm using ETT Bruce Protocol at week 4

    • Duration of exercise before the onset of angina or ST-segment depression (min)
    • Max. work load (Mets)
    • Max. ST depression (mm)
    • HR at max. ST depression (beats/min)
    • Syst. BP at max ST dep. (mm/Hg)

    other measures are:

    • Decrease in the frequency of anginal attacks
    • Use of rescue medicines
    • Adverse events reported

Estimated Enrollment: 40
Study Start Date: September 2011
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nicorandil test arm
Nicorandil is given with atenolol therapy.
Drug: Nicorandil
Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
Other Name: Nicorandil/ Nicoril
Active Comparator: Atenolol control arm
Atenolol 50 mg OD is given.
Drug: Atenolol
Patients in the control arm would be advised atenolol 50 mg od
Other Name: Atenolol/Atenorm

  Show Detailed Description


Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes.
  2. Male and female
  3. Age 25 to 65 years
  4. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards.
  5. Patient must be able to give voluntary written informed consent.

Exclusion Criteria:

  1. Hypertension of > 170/100 mm of Hg
  2. Valvular heart disease and cardiomyopathy
  3. Myocardial infarction in < 6 months
  4. Unstable angina
  5. Congestive cardiac failure
  6. Severe anemia (Hb 7G/dl)
  7. Cardiac arrhythmias or II or III degree AV block
  8. Significant liver or renal dysfunction
  9. IDDM (Type-1 diabetes mellitus)
  10. Systolic blood pressure < 100 mm Hg
  11. Pregnant and nursing women
  12. Known hypersensitivity to nicorandil
  13. On calcium channel blockers
  14. Patients not eligible for Tc 99m SPECT
  15. Patients in whom beta blockers are contraindicated
  16. Geographical inaccessibility for treatment or follow-up evaluations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01397994

Contact: Tariq Ashraf, MBBS,FCPS,FACC,FSCAI 092-03222999914
Contact: Hamid Tirmizey, MBBS,BSC,DIP.CARD. 092-03212215383

National Institute of Cardiovascular Diseases Recruiting
Karachi, Sind, Pakistan, 75850
Contact: Tariq Ashraf, MBBS, FCPS, FACC, FSCAI    092-03222999914   
Contact: Hamid Tirmizey, MBBS, BSC, DIP. CARD    092-03212215383   
Principal Investigator: Tariq Ashraf, MBBS, FCPS, FACC, FSCAI         
Sponsors and Collaborators
Ferozsons Laboratories Ltd.
Principal Investigator: Tariq Ashraf, MBBS,FCPS,FACC,FSCAI National Institute of Cardiovascular Diseases
  More Information

Responsible Party: Dr. Tariq Ashraf, Assistant Professor Of cardiology, National Institute of Cardiovascular Diseases, Ferozsons Laboratories Ltd. Identifier: NCT01397994     History of Changes
Other Study ID Numbers: FZS NICORIL STUDY 01 
Study First Received: July 18, 2011
Last Updated: December 7, 2011
Health Authority: Pakistan: Research Ethics Committee

Keywords provided by Ferozsons Laboratories Ltd.:
Nicorandil therapy in patients of chronic stable angina

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Cardiovascular Diseases
Chest Pain
Heart Diseases
Myocardial Ischemia
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Vascular Diseases
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Growth Substances
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Vasodilator Agents
Vitamin B Complex
Vitamins processed this record on May 30, 2016